Equities

Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)49.35
  • Today's Change-0.745 / -1.49%
  • Shares traded281.44k
  • 1 Year change+6.81%
  • Beta0.8276
Data delayed at least 15 minutes, as of Sep 20 2024 20:14 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy1
Outperform3
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The 4 analysts offering 12 month price targets for Amphastar Pharmaceuticals Inc have a median target of 60.50, with a high estimate of 70.00 and a low estimate of 48.00. The median estimate represents a 20.78% increase from the last price of 50.09.
High39.7%70.00
Med20.8%60.50
Low-4.2%48.00

Earnings history & estimates in USD

On Aug 07, 2024, Amphastar Pharmaceuticals Inc reported 2nd quarter 2024 earnings of 0.94 per share. This result exceeded the 0.77 consensus of the 6 analysts covering the company and exceeded last year's 2nd quarter results by 44.62%.
The next earnings announcement is expected on Nov 06, 2024.
Average growth rate+15.50%
Amphastar Pharmaceuticals Inc reported annual 2023 earnings of 3.32 per share on Feb 29, 2024.
Average growth rate+76.04%
More ▼

Revenue history & estimates in USD

Amphastar Pharmaceuticals, Inc. had 2nd quarter 2024 revenues of 182.39m. This bettered the 170.94m consensus of the 6 analysts covering the company. This was 30.26% above the prior year's 2nd quarter results.
Average growth rate+6.29%
Amphastar Pharmaceuticals, Inc. had revenues for the full year 2023 of 644.40m. This was 29.14% above the prior year's results.
Average growth rate+19.20%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.